Shares of STAAR Surgical (NASDAQ: STAA) rose 23.7% this week, according to data provided by S&P Global Market Intelligence. The stock has fallen more than 27% over the past 12 months.

STAAR makes and sells foldable implantable lenses for the eye, along with their delivery systems, eliminating the need in some cases for contacts or glasses. The foldable lenses allow surgeons to implant them in the eye using a small incision. 

Investors were encouraged when new CEO Tom Frinzi purchased shares of the company this week. Frinzi, who took over from the retiring Caren Mason on Dec. 19, bought 87,805 shares of STAAR stock on Monday.

Continue reading

Source Fool.com